Clinical factors and XXXX in @entity1478 . Analysis of 1027 cases.

@entity1 @entity1204 @entity440 @entity1127 @entity101 @entity5 @entity6 @entity28 @entity1478
STUDY OBJECTIVE: To assess the prevalence of @entity1127 carrying a @entity5 and match association between clinical factors and oncologic progression. STUDY DESIGN: A retrospective study (Canadian Task Force classification II-3) at a university hospital in Rome, Italy. We retrospectively analyzed data from 1027 @entity1 consecutively treated for @entity1478 at our center in the period 2002-2011. The association of @entity5 with hormonal status, @entity440 , @entity101 , symptoms, @entity6 , @entity28 , and hormonal replacement therapy in pre- and post-menopausal @entity1 was assessed. RESULTS: Mean age was 45.8  10.8 years. @entity1127 accounted for 95.8% of the total, pre-malignant for 2.67%, malignant for 1.54%. Our data showed that post-menopausal and older @entity1 (>60y) with @entity1478 have a higher risk of developing a related @entity1204 (OR: 3.05, 95% CI [1.54, 6.19], p<0.001 and OR: 2.8, 95% CI [1.38, 5.56], p <=0.003. Also we observed that @entity1 with AUB in the post-menopausal period displayed a risk of @entity5 (OR: 31.1, 95% CI [10.3,111], p value <0.001). CONCLUSION: Special attention should be drawn to symptomatic post-menopausal @entity1 that appear to be at higher risk of @entity5 . Symptomatic pre-menopausal @entity1 and asymptomatic post-menopausal @entity1 with @entity1127 may be a group with intermediate-risk. These @entity1 should undergo an individualized management plan, balancing both risks and benefits of surgical intervention after discussion with the @entity1 .
